Abstract 161P
Background
Targeted therapy and Immunotherapy have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC), particularly adenocarcinoma (AC). Among NSCLC cases, around 8-10% are ALK positive with the majority involving EML4-ALK gene variants. This study aims to explore the connection between ALK gene variants and PDL1 expression in metastatic lung AC, as there is limited data from the Indian cohort on this subject.
Methods
A retrospective analysis was conducted on data collected from 17 advanced lung AC patients with ALK gene mutations. The ALK protein variants were determined through Next-Generation Sequencing, while PDL1 expression was assessed using Immunohistochemistry with sP263 antibody. These findings were then correlated with relevant clinical parameters.
Results
The median age of the patient cohort was 46 years (range 28 to 65). Among the 17 ALK-positive, the majority had EML4-ALK gene fusions, with V1 (47.05%), V3 (35.2%), and V2 (11.7%) being the most common variants. V1 was more prevalent in females (87.5%) than males (12.5%). PDL1 negativity was observed in 64.7% of patients, while 35.2% were PDL1 positive. Specifically, PDL1 negativity was more common in the V1 variant, whereas PDL1 positivity was associated with V3. Brain metastases were more frequent in the PDL1-negative cohort (35.2%), and bone metastases and malignant pleural effusions were more common in V1 compared to V2 and V3. Table: 161P
ALK metastatic sites | Frequency |
Malignant pleural effusion | 70.5% |
Brain metastasis | 35.2% |
Bone metastasis | 35.2% |
Contralateral lung involvement | 23.5% |
Liver metastasis | 11.7% |
Conclusions
The study concludes that V1 and V3 EML4-ALK gene variants are prevalent in metastatic lung AC patients. It reveals a significant association between PDL1 expression and specific ALK variants, with V1 being more frequently associated with PDL1 negativity and V3 with PDL1 positivity. Additionally, the V1 and V3 variants were more commonly found in female patients and were associated with brain metastases. This real-world experience contributes valuable insights into treatment responses in this specific patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract